American Diabetes Association
No_line_2022_06_09_DKD_Prevention_in_DECLARE-TIMI_58_-_supp_-clean.pdf (1.07 MB)

Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

Download (1.07 MB)
posted on 2022-08-23, 12:07 authored by Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P.H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine


Objective: In patients with moderate-severe albuminuric kidney disease, sodium-glucose co-transporter-2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type-2 diabetes (T2D), focusing on populations with low kidney risk. 

Methods: In the DECLARE-TIMI 58 trial, patients with T2D at high cardiovascular risk were randomly assigned to dapagliflozin versus placebo. Outcomes were analyzed by treatment arms, overall, and by Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. The prespecified kidney-specific composite outcome was sustained decline ≥40% in estimated glomerular filtration rate (eGFR) to<60mL/min/1.73m², end-stage kidney disease, and kidney-related death. Other outcomes included incidence of categorical eGFR decline of different thresholds and chronic (6-months to 4-year) or total (baseline to 4-year) eGFR slopes. 

Results: Most participants were in the low-moderate KDIGO risk categories (n=15,201, 90.3%). The hazard for the kidney-specific composite outcome was lower with dapagliflozin across all KDIGO risk categories (P-interaction 0.97), including those at low risk (HR 0.54, 95%CI 0.38-0.77). Risks for categorical eGFR reductions (≥57% [in those with baseline eGFR≥60ml/min/1.73m2], ≥50%, ≥40%, and ≥30%) were lower with dapagliflozin (HR= 0.52, 0.57, 0.55, and 0.70, respectively, p<0.05). Slopes of eGFR decline favored dapagliflozin across KDIGO risk categories, including the low KDIGO risk (between-arm differences of 0.87 [chronic] and 0.55 [total] mL/min/1.73 m²/year; p<0.0001). 

Conclusion: Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.  


The DECLARE–TIMI 58 trial was initially funded by AstraZeneca and Bristol-Myers Squibb. By the time of publication, AstraZeneca was the sole funder.


Usage metrics

    Diabetes Care


    Ref. manager